Christopher Cannon/LinkedIn
Feb 16, 2026, 13:21
Christopher Cannon: Factor XIa Inhibition Reduces Stroke Risk in Non-Cardioembolic Stroke and High-Risk TIA
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn:
”Factor XIa inhibition works! When added to antiplatelet therapy for non-cardioembolic ischemic stroke or high-risk TIA, XIa inhibition significantly reduced stroke by 26%, with no significant increase in bleeding!”
Title: Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%— Asundexian prevented repeat strokes without bleeding side effects
Authors: Nicole Lou
Read the Full Article on MedPage Today։
Stay updated on all scientific advances with Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque